{"disease":{"id":"refractory-metastatic-colorectal-cancer","name":"refractory metastatic colorectal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06202417","title":"Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study","phase":"","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04737187","title":"Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":492,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT07261709","title":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":236,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04527068","title":"QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05213195","title":"NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06522919","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT05733611","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Replimune, Inc.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}